Is 3 months of romosozumab noninferior to 12 months for increasing hip BMD in postmenopausal osteoporosis?

In postmenopausal women at high fracture risk, 3 months of romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab for increasing total hip BMD over 12 months.

Randomised trial · Lancet Diabetes & Endocrinology 2026

Reference: Leder BZ, Ramchand SK, Jordan M, et al. Lancet Diabetes Endocrinol. 2026;14(3):216-222. PMID:41621431. https://pubmed.ncbi.nlm.nih.gov/41621431/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en